###begin article-title 0
###xml 14 19 14 19 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Trim5</italic>
###xml 60 65 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
The Effect of Trim5 Polymorphisms on the Clinical Course of HIV-1 Infection
###end article-title 0
###begin p 1
###xml 311 316 299 304 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Trim5</italic>
###xml 397 405 381 389 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 539 544 523 528 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Trim5</italic>
###xml 774 782 754 762 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 1119 1122 1099 1102 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4.5</sup>
###xml 1530 1535 1506 1511 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Trim5</italic>
###xml 1656 1663 1628 1635 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 149 154 <span type="species:ncbi:9606">human</span>
###xml 185 190 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 204 209 <span type="species:ncbi:9606">human</span>
###xml 240 245 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 422 434 <span type="species:ncbi:9606">participants</span>
###xml 626 631 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1077 1082 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1261 1266 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1578 1583 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1650 1655 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
The antiviral factor tripartite interaction motif 5alpha (Trim5alpha) restricts a broad range of retroviruses in a species-specific manner. Although human Trim5alpha is unable to block HIV-1 infection in human cells, a modest inhibition of HIV-1 replication has been reported. Recently two polymorphisms in the Trim5 gene (H43Y and R136Q) were shown to affect the antiviral activity of Trim5alpha in vitro. In this study, participants of the Amsterdam Cohort studies were screened for polymorphisms at amino acid residue 43 and 136 of the Trim5 gene, and the potential effects of these polymorphisms on the clinical course of HIV-1 infection were analyzed. In agreement with the reported decreased antiviral activity of Trim5alpha that contains a Y at amino acid residue 43 in vitro, an accelerated disease progression was observed for individuals who were homozygous for the 43Y genotype as compared to individuals who were heterozygous or homozygous for the 43H genotype. A protective effect of the 136Q genotype was observed but only after the emergence of CXCR4-using (X4) HIV-1 variants and when a viral load of 104.5 copies per ml plasma was used as an endpoint in survival analysis. Interestingly, naive CD4 T cells, which are selectively targeted by X4 HIV-1, revealed a significantly higher expression of Trim5alpha than memory CD4 T cells. In addition, we observed that the 136Q allele in combination with the -2GG genotype in the 5'UTR was associated with an accelerated disease progression. Thus, polymorphisms in the Trim5 gene may influence the clinical course of HIV-1 infection also underscoring the antiviral effect of Trim5alpha on HIV-1 in vivo.
###end p 1
###begin title 2
Author Summary
###end title 2
###begin title 3

###end title 3
###begin p 4
###xml 211 241 211 241 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">tripartite interaction motif 5</italic>
###xml 248 253 248 253 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Trim5</italic>
###xml 655 663 647 655 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 687 695 679 687 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 889 892 881 884 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4.5</sup>
###xml 1004 1009 996 1001 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Trim5</italic>
###xml 1110 1117 1098 1105 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 23 28 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 411 416 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 430 442 <span type="species:ncbi:9606">participants</span>
###xml 740 745 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 849 854 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1052 1057 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1104 1109 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
The clinical course of HIV-1 infection is highly variable between individuals, and host genetic variations may at least account for part of these differences. Recently two single nucleotide polymorphisms in the tripartite interaction motif 5 gene (Trim5) have been reported to affect the antiviral activity of the Trim5alpha protein. Here we analyzed the effect of these polymorphisms on the clinical course of HIV-1 infection in participants of the Amsterdam Cohort studies. We observed an accelerated disease progression for individuals who were homozygous for the 43Y genotype that has been associated with a decreased antiviral activity of Trim5alpha in vitro. The 136Q genotype has in vitro been associated with a slightly higher anti-HIV-1 activity. We observed a protective effect of the 136Q genotype only after the emergence of CXCR4-using HIV-1 variants using viral load above 104.5 copies per ml plasma as an endpoint in survival analysis. These results suggest that genetic variations in the Trim5 gene may influence the clinical course of HIV-1 infection and confirm a role of Trim5alpha on HIV-1 in vivo.
###end p 4
###begin title 5
Introduction
###end title 5
###begin p 6
###xml 415 416 415 416 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0040018-b001">1</xref>
###xml 417 418 417 418 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0040018-b004">4</xref>
###xml 512 513 512 513 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0040018-b005">5</xref>
###xml 514 515 514 515 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0040018-b008">8</xref>
###xml 22 27 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 273 278 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
The susceptibility to HIV-1 infection and subsequent disease progression is highly variable between individuals. Host genetic variations have previously been demonstrated to account for at least part of these differences. Polymorphisms in chemokine receptors that serve as HIV-1 coreceptors, or in their natural ligands, have been associated with reduced susceptibility to infection as well as disease progression [1-4]. Furthermore, certain HLA types have been correlated with the clinical course of infection [5-8].
###end p 6
###begin p 7
###xml 370 371 362 363 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0040018-b009">9</xref>
###xml 372 374 364 366 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0040018-b010">10</xref>
###xml 594 596 582 584 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0040018-b011">11</xref>
###xml 597 599 585 587 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0040018-b019">19</xref>
###xml 706 708 690 692 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0040018-b020">20</xref>
###xml 709 711 693 695 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0040018-b026">26</xref>
###xml 1290 1292 1258 1260 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0040018-b027">27</xref>
###xml 106 112 <span type="species:ncbi:9606">humans</span>
###xml 116 121 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 311 316 <span type="species:ncbi:9606">human</span>
###xml 325 330 <span type="species:ncbi:9606">human</span>
###xml 727 732 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 785 800 <span type="species:ncbi:9544">rhesus macaques</span>
###xml 805 826 <span type="species:ncbi:9534">African green monkeys</span>
###xml 836 839 <span type="species:ncbi:11723?0.9432672590567327|species:ncbi:12845?0.02460697197539303">SIV</span>
###xml 882 902 <span type="species:ncbi:9534">African green monkey</span>
###xml 904 909 <span type="species:ncbi:9606">Human</span>
###xml 957 963 <span type="species:ncbi:9796">equine</span>
###xml 1032 1037 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1071 1076 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1115 1120 <span type="species:ncbi:9606">human</span>
###xml 1262 1267 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1472 1477 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Variations in genes involved in innate immunity may also contribute to the differential susceptibility of humans to HIV-1 infection and the highly variable outcome of the disease. Recently, the tripartite interaction motif 5alpha (Trim5alpha) has been identified as part of the intrinsic immunity that protects human and non-human primates against retroviral infection [9,10]. Trim5alpha targets the capsid of the incoming retrovirus in the cytoplasm directly after entry and interferes with viral replication at an early post-entry step most likely at the poorly understood uncoating process [11-19]. Species-specific variations in Trim5alpha account for the restriction pattern of specific retroviruses [20-26]. For example, HIV-1 replication is blocked efficiently by Trim5alpha of rhesus macaques and African green monkeys, whereas SIV-mac is only restricted by Trim5alpha from African green monkey. Human Trim5alpha efficiently blocks N-tropic MLV and equine infectious anaemia virus, but is much less efficient in restricting HIV-1 replication. This indicates that HIV-1 has at least partially adapted to the human variant of this restriction factor. Recently, we observed that Trim5alpha escape variants developed late in infection in a proportion of the HIV-1 infected individuals [27]. The emergence of the escape variants was preceded by a prolonged asymptomatic phase, indicating that Trim5alpha mediated suppression of viral replication indeed plays a role in HIV-1 pathogenesis.
###end p 7
###begin p 8
###xml 47 52 47 52 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Trim5</italic>
###xml 109 111 109 111 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0040018-b028">28</xref>
###xml 112 114 112 114 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0040018-b031">31</xref>
###xml 191 196 191 196 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Trim5</italic>
###xml 328 330 324 326 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0040018-b028">28</xref>
###xml 331 333 327 329 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0040018-b030">30</xref>
###xml 437 439 429 431 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0040018-b028">28</xref>
###xml 440 442 432 434 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0040018-b030">30</xref>
###xml 535 543 523 531 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 545 547 533 535 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0040018-b028">28</xref>
###xml 548 550 536 538 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0040018-b030">30</xref>
###xml 654 656 638 640 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0040018-b030">30</xref>
###xml 827 829 811 813 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0040018-b030">30</xref>
###xml 883 885 867 869 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0040018-b029">29</xref>
###xml 886 888 870 872 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0040018-b030">30</xref>
###xml 933 938 917 922 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Trim5</italic>
###xml 1007 1009 991 993 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0040018-b029">29</xref>
###xml 1010 1012 994 996 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0040018-b031">31</xref>
###xml 1013 1015 997 999 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0040018-b032">32</xref>
###xml 61 66 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 517 522 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 624 629 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 766 771 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 957 962 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
The potential role of polymorphisms within the Trim5 gene on HIV-1 susceptibility has recently been studied [28-31]. Of the eight nonsynonymous polymorphisms that have been identified in the Trim5 gene, two have been reported to have functional consequences with regard to the antiviral activity of Trim5alpha (H43Y and R136Q) [28,30]. The H43Y is located in the RING domain of Trim5alpha and may impair its putative E3 ligase activity [28,30]. Indeed, the 43Y variant of Trim5alpha was less efficient in restricting HIV-1 replication in vitro [28,30]. The R136Q polymorphism has been associated with a slightly higher anti-HIV-1 activity of Trim5alpha [30]. In agreement, the R136Q polymorphism was more frequently observed in high risk seronegative as compared to HIV-1 infected individuals in a cohort of African Americans [30], although not confirmed in other study populations [29,30]. So far no significant association between Trim5 polymorphisms and HIV-1 disease progression have been demonstrated [29,31,32].
###end p 8
###begin p 9
###xml 259 264 255 260 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Trim5</italic>
###xml 100 105 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 119 131 <span type="species:ncbi:9606">participants</span>
###xml 311 316 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Here we studied the effect of the Trim5alpha H43Y and R136Q polymorphisms on the clinical course of HIV-1 infection in participants of the Amsterdam Cohort studies. In addition, we analyzed whether the R136Q genotype in combination with a SNP in the 5'UTR of Trim5 (-2G/C) was associated with susceptibility to HIV-1 infection or disease progression.
###end p 9
###begin title 10
Results
###end title 10
###begin title 11
###xml 31 36 31 36 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Trim5</italic>
Distribution of H43Y and R136Q Trim5 Genotypes
###end title 11
###begin p 12
###xml 1023 1025 1019 1021 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0040018-b029">29</xref>
###xml 1026 1028 1022 1024 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0040018-b031">31</xref>
###xml 77 82 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 92 104 <span type="species:ncbi:9606">participants</span>
###xml 223 228 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 238 250 <span type="species:ncbi:9606">participants</span>
###xml 415 427 <span type="species:ncbi:9606">participants</span>
###xml 1130 1135 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
The prevalence of Trim5alpha polymorphisms H43Y and R136Q was studied in 327 HIV-1 positive participants of the Amsterdam Cohort studies. For the H43Y polymorphism a minor allele frequency of 0.115 was observed. Of the 327 HIV-1 positive participants, 61 (18.7%) were heterozygous and 7 (2.1%) were homozygous for the 43Y allele. The R136Q polymorphism was observed at a minor allele frequency of 0.379. Of the 327 participants, 156 (47.7%) were heterozygous and 46 (14.1%) were homozygous for the 136Q allele. Six mutually exclusive haplotypes were observed for the combination of R136Q and H43Y polymorphisms: 43HH/136RR (n = 88), 43HH/136RQ (n = 125), 43HH/136QQ (n = 46), 43HY/136RQ (n = 31), 43HY/136RR (n = 30) and 43YY/136RR (n = 7). The 43Y polymorphism was not observed in the group homozygous for the 136QQ genotype and the 136Q polymorphism was never observed in combination with a homozygous 43YY genotype, also confirming that the 43Y polymorphism and the 136Q polymorphism are not located on the same allele [29,31]. No significant differences in the H43Y or R136Q minor allele frequencies were observed between the HIV-1 seropositive individuals and healthy controls (allele frequencies of 0.106 and 0.389 for H43Y and R136Q, respectively).
###end p 12
###begin title 13
###xml 19 24 19 24 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Trim5</italic>
###xml 60 65 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Effect of the H43Y Trim5 Genotype on the Clinical Course of HIV-1 Infection
###end title 13
###begin p 14
###xml 180 183 179 182 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4.5</sup>
###xml 277 282 276 281 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Trim5</italic>
###xml 480 481 479 480 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 500 501 499 500 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 590 598 589 597 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0040018-g001">Figure 1</xref>
###xml 604 605 603 604 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0040018-g001">1</xref>
###xml 608 615 607 614 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="ppat-0040018-t001">Table 1</xref>
###xml 745 753 743 751 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0040018-g001">Figure 1</xref>
###xml 756 763 754 761 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="ppat-0040018-t001">Table 1</xref>
###xml 888 891 886 889 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4.5</sup>
###xml 924 925 922 923 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0040018-b001">1</xref>
###xml 956 959 954 957 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4.5</sup>
###xml 1130 1138 1128 1136 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0040018-g001">Figure 1</xref>
###xml 1141 1148 1139 1146 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="ppat-0040018-t001">Table 1</xref>
###xml 1237 1245 1235 1243 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0040018-g001">Figure 1</xref>
###xml 795 807 <span type="species:ncbi:9606">participants</span>
###xml 899 904 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Kaplan Meier and Cox Proportional Hazard analysis with clinical AIDS (Definition CDC 1987 and 1993), CD4 T cell counts below 200 cells/mul blood, and plasma viral RNA load above 104.5 copies per ml plasma were used as end points to determine the effect of polymorphisms in the Trim5 gene on disease progression. We observed an accelerated disease progression in the group homozygous for the 43Y allele relative to the 43 HH wild type genotype, with a relative hazard (RH) of 3.1 (p = 0.006) and 2.8 (p = 0.007) for AIDS diagnosis according to the 1987 or 1993 CDC definition, respectively (Figure 1A and 1B; Table 1). An accelerated progression rate was also observed when CD4 T cell counts below 200 cells per mul blood were used as end point (Figure 1C; Table 1). The median viral RNA load of participants of the Amsterdam cohort progressing to AIDS has previously been determined at 104.5 copies HIV-1 RNA per ml plasma [1]. When viral RNA load above 104.5 copies per ml plasma was used as endpoint in the survival analysis, we again observed an accelerated disease progression for individuals homozygous for the 43Y genotype (Figure 1D; Table 1). The heterozygous genotype (43HY) was not associated with delayed disease progression (Figure 1).
###end p 14
###begin title 15
Survival Analysis for the H43Y Genotype
###end title 15
###begin p 16
###xml 230 233 229 232 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4.5</sup>
Kaplan Meier analysis for time in years from seroconversion to AIDS according to the CDC 1987 definition (A), to AIDS according to the CDC 1993 definition (B), to CD4 count below 200 cells/mul blood (C), to viral RNA load above 104.5 copies per ml plasma (D), and to first detection of X4-variants (E) based on the H43Y genotype. Bold lines indicate individuals with the wild type genotype (43HH); dashed black lines indicate individuals heterozygous for the 43Y genotype (43HY); thin black lines indicate individuals homozygous for the 43Y genotype (43YY).
###end p 16
###begin p 17
Cox Regression Analysis for Progression to AIDS, CD4 Cells <200 Cells/mul, and X4-Variant Development
###end p 17
###begin p 18
###xml 128 130 128 130 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0040018-b033">33</xref>
###xml 621 629 621 629 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0040018-g001">Figure 1</xref>
###xml 632 639 632 639 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="ppat-0040018-t001">Table 1</xref>
###xml 27 32 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 148 153 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Development of CXCR4 using HIV-1 variants (X4-variants) has previously been associated with an accelerated disease progression [33]. The ability of HIV-1 variants to use CXCR4 as a coreceptor and replicate in MT2 cells was analyzed routinely during follow-up in the cohort studies in 319 of 327 individuals from our study population. During the course of infection X4-variants developed in 126 individuals. No association between the prevalence of X4-variants and the H43Y genotype could be observed (data not shown). However, X4-variants did develop more rapidly in individuals who were homozygous for the 43Y genotype (Figure 1E; Table 1).
###end p 18
###begin p 19
###xml 179 181 179 181 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0040018-b034">34</xref>
###xml 38 50 <span type="species:ncbi:9606">participants</span>
###xml 73 78 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 129 141 <span type="species:ncbi:9606">participants</span>
###xml 211 223 <span type="species:ncbi:9606">participants</span>
###xml 339 351 <span type="species:ncbi:9606">participants</span>
Our study population consisted of 130 participants who seroconverted for HIV-1 antibodies during follow-up and 197 seroprevalent participants with an imputed seroconversion date [34]. Inclusion of seroprevalent participants in our analysis did not bias our data and Cox regression analysis stratifying for seroconvertors and seroprevalent participants gave similar results (data not shown).
###end p 19
###begin title 20
###xml 20 25 20 25 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Trim5</italic>
###xml 61 66 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Effect of the R136Q Trim5 Genotype on the Clinical Course of HIV-1 Infection
###end title 20
###begin p 21
###xml 64 69 64 69 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Trim5</italic>
###xml 235 238 234 237 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4.5</sup>
###xml 96 101 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 608 613 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Next we examined a potential role for the R136Q polymorphism in Trim5 on the clinical course of HIV-1 infection. Using clinical AIDS (Definition CDC 1987 and 1993), CD4 T cell counts below 200 cells/mul blood or viral RNA load above 104.5 copies per ml plasma as endpoint in Kaplan Meier and Cox proportional hazard analysis, no significant associations between the 136RQ or 136QQ genotype and the clinical course of infection were revealed (data not shown). The R136Q polymorphism also had no effect on the time to first detection of X4-variants (data not shown). In addition, the prevalence of CXCR4 using HIV-1 variants was not associated with the R136Q genotype.
###end p 21
###begin p 22
###xml 57 62 57 62 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Trim5</italic>
###xml 587 590 587 590 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4.5</sup>
###xml 663 664 663 664 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 684 685 684 685 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 801 809 801 809 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0040018-g002">Figure 2</xref>
###xml 811 818 811 818 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="ppat-0040018-t002">Table 2</xref>
###xml 1194 1201 1193 1200 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="ppat-0040018-t002">Table 2</xref>
###xml 234 239 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 527 539 <span type="species:ncbi:9606">participants</span>
Next we analyzed whether a potential effect of the R136Q Trim5 genotype was dependent on the coreceptor usage of the virus present. The R136Q genotype had no significant effect on the clinical course of infection when only CCR5 using HIV-1 variants (R5-variants) were present irrespective the end point used in the survival analysis (data not shown). However, a significant protective effect on disease progression associated with the R136Q genotype was observed after X4-variant development using the median viral RNA load of participants of the Amsterdam cohort progressing to AIDS (104.5 copies per ml) as an end point in survival analysis, with a RH of 0.44 (p = 0.008) and 0.26 (p = 0.030) for the heterozygous 136RQ and homozygous 136QQ genotype, respectively as compared to the 136RR genotype (Figure 2; Table 2). At the moment of X4-development the viral load of individuals who were homozygous (QQ), heterozygous (RQ) or wild type (RR) for the amino acid residue at position 136 was similar (data not shown). The R136Q polymorphism was not associated with disease progression after X4-variant development using clinical AIDS or CD4 cell counts below 200 cells mul blood as end points (Table 2).
###end p 22
###begin title 23
Survival Analysis for R136Q Genotype after Emergence of X4-Variants
###end title 23
###begin p 24
###xml 116 119 116 119 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4.5</sup>
Kaplan Meier analysis for time in years from the moment of first detection of X4-variants to viral RNA load above 104.5 copies per ml plasma based on the R136Q genotype. Bold black lines indicate individuals with the wild type genotype (136RR); dashed black lines indicate individuals heterozygous for the 136Q genotype (136RQ); thin black lines indicate individuals homozygous for the 136Q genotype (136QQ).
###end p 24
###begin p 25
###xml 96 99 95 98 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4.5</sup>
Cox Regression Analysis for Progression to AIDS, CD4 Cells <200 Cells/mul, or Viral RNA Load >104.5/ml after X4-Variant Development
###end p 25
###begin title 26
Trim5alpha mRNA Expression Levels in Naive and Memory CD4 T Cells
###end title 26
###begin p 27
###xml 369 371 361 363 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0040018-b035">35</xref>
###xml 372 374 364 366 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0040018-b036">36</xref>
###xml 705 712 693 700 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 1148 1149 1121 1122 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 1160 1168 1133 1141 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0040018-g003">Figure 3</xref>
###xml 238 243 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
The protective effect of the 136Q Trim5alpha variant on disease progression only after emergence of X4 variants may imply that Trim5alpha has a stronger effect on X4 variants than on R5 variants. Previously we demonstrated that R5 and X4 HIV-1 variants partially reside in different CD4 T cell compartments due to differential expression of coreceptors CCR5 and CXCR4 [35,36]. R5 variants were selectively isolated from CD4 memory T cells, whereas X4 variants were isolated from memory and naive CD4 T cells. Here we analyzed whether differences of the Trim5alpha mRNA levels in naive and memory CD4 T cell populations could contribute to the differential effect of the 136Q variant on X4 and R5 variants in vivo. Naive and memory CD4 T cells were isolated from PBMC from 12 healthy controls by FACS sorting based on CD45RO and CD27 expression and Trim5alpha mRNA levels were analyzed by quantitative real time PCR. To correct for differences in input, Trim5alpha mRNA levels were normalized for beta-actin mRNA levels. Trim5alpha mRNA levels were significantly higher in naive (CD45RO-CD27+) CD4 T cells as compared to memory (CD45RO+) CD4 cells (p = 0.019) (Figure 3A).
###end p 27
###begin title 28
Analysis of Trim5alpha mRNA Levels in Naive and Memory CD4 T Cells
###end title 28
###begin p 29
(A) Trim5alpha mRNA levels in naive CD4 T cells (CD45RO-CD27+) and memory CD4 T cells (CD45RO+) obtained from healthy controls.
###end p 29
###begin p 30
###xml 103 108 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
(B) Average Trim5alpha mRNA levels in naive and memory CD4 T cells during the course of infection from HIV-1 infected individuals. Trim5alpha mRNA levels are normalized for beta-actin mRNA levels. Different symbols represent Trim5alpha mRNA levels of naive and memory CD4 T cells from the different individuals.
###end p 30
###begin p 31
###xml 408 409 396 397 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 420 428 408 416 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0040018-g003">Figure 3</xref>
###xml 85 90 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
In addition, Trim5alpha mRNA levels in naive and memory CD4 T cells were analyzed in HIV-1 positive individuals early and late in the course of infection (23 PBMC samples from 11 individuals). Although no differences in Trim5alpha mRNA levels were observed during the course of infection, we again observed a significantly higher Trim5alpha mRNA level in naive CD4 T cells as compared to memory CD4 T cells (p = 0.003) (Figure 3B).
###end p 31
###begin title 32
###xml 66 71 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Effect of Combined R136Q and -2G/C Genotypes on Susceptibility to HIV-1 Infection and Disease Progression
###end title 32
###begin p 33
###xml 66 71 66 71 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Trim5</italic>
###xml 286 288 286 288 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0040018-b029">29</xref>
###xml 191 196 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 373 378 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 580 585 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 817 822 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Recently a G to C polymorphism at position -2 in the 5'UTR of the Trim5 gene (-2G/C; rs3824949) in combination with the R136Q polymorphism has been associated with enhanced susceptibility to HIV-1 infection (136Q/-2G haplotype) and accelerated disease progression (136R/-2G haplotype) [29]. To analyze whether the combined R136Q and -2G/C genotype was also associated with HIV-1 susceptibility or disease progression in our study population, we genotyped our study population for the G to C polymorphism at position -2 (-2G/C). The -2C allele frequency was 0.486 and 0.418 in our HIV-1 positive individuals and healthy controls, respectively. When the -2G/C genotype was analyzed in combination with the R136Q genotype no significant differences in the distribution of the combined genotypes was observed between the HIV-1 infected individuals and the healthy controls. The -2GG genotype was not observed in combination with the homozygous 136Q genotype in both study populations.
###end p 33
###begin p 34
###xml 317 318 317 318 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 371 372 371 372 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 407 415 407 415 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-0040018-g004">Figure 4</xref>
###xml 463 465 463 465 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0040018-b029">29</xref>
Next we analyzed the effect of the combined R136Q and -2G/C genotypes on disease progression using clinical AIDS (Definition CDC 1993) as an end point. Individuals carrying the 136Q allele (136RQ and 136QQ) in combination with the -2GG genotype showed an accelerated progression to disease in comparison to the -2GC (p = 0.009; RH 2.6; 95% CI 1.3-5.2) and -2CC genotype (p = 0.056; RH 2.1; 95% CI 1.0-4.3) (Figure 4). In contrast to the study by Speelmon et al. [29], no significant effect of the -2G/C genotype on disease progression was observed in the group with the 136RR genotype.
###end p 34
###begin title 35
Survival Analysis for the -2G/C Genotype in Combination with the 136Q Genotype
###end title 35
###begin p 36
Kaplan Meier analysis for time in years from seroconversion to AIDS according to the CDC 1993 definition. Bold black lines indicate individuals with the -2GG genotype; dashed black lines indicate individuals with the -2GC genotype; thin black lines indicate individuals with the -2CC genotype.
###end p 36
###begin title 37
AIDS Incidence in Relation to H43Y Genotype and Other Progression Markers
###end title 37
###begin p 38
###xml 98 103 98 103 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Trim5</italic>
###xml 269 273 269 273 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCR5</italic>
###xml 284 285 284 285 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0040018-b001">1</xref>
###xml 429 432 428 431 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4.5</sup>
###xml 606 611 605 610 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCR5-</italic>
###xml 616 618 611 613 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">32</italic>
###xml 653 660 648 655 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="ppat-0040018-t003">Table 3</xref>
###xml 804 807 798 801 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4.5</sup>
###xml 883 888 877 882 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Trim5</italic>
###xml 963 970 957 964 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="ppat-0040018-t003">Table 3</xref>
###xml 1078 1083 1072 1077 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCR5-</italic>
###xml 1088 1090 1078 1080 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">32</italic>
Uni- and multivariate relative hazard analysis were used to determine the predictive value of the Trim5 H43Y genotype (43YY) in combination with previously established prediction markers such as CD4 T cell count, plasma viral RNA load, the presence of X4-variants, and CCR5-genotype [1]. Univariate analysis indicated that homozygosity for the H43Y polymorphism, CD4 T cell counts below 500 cells per mul, viral RNA load above 104.5 copies per ml plasma and the presence of X4-variants at 18-30 months after seroconversion were predictive for more rapid progression to AIDS, whereas heterozygosity for the CCR5-Delta32 genotype had a protective effect (Table 3). Multivariate analysis at 2 years after seroconversion indicated that CD4 T cell counts below 500 cells per mul blood, viral RNA load above 104.5 copies per ml plasma, the presence of X4-variants and homozygosity for the Trim5 H43Y genotype (43YY) were independent predictors for progression to AIDS (Table 3). In our study population the homozygous H43Y genotype was not observed in combination with a heterozygous CCR5-Delta32 genotype excluding this parameter from the multivariate analysis.
###end p 38
###begin p 39
###xml 175 179 175 179 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCR5</italic>
Univariate and Multivariate Relative Hazards for Progression to AIDS (CDC 1987) for the H43Y Genotype, Presence of X4-Variants, CD4 T Cell Count, Viral RNA Load in Plasma, or CCR5 Genotype at Two Years after Seroconversion
###end p 39
###begin title 40
Discussion
###end title 40
###begin p 41
###xml 438 440 422 424 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0040018-b027">27</xref>
###xml 615 617 595 597 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0040018-b011">11</xref>
###xml 618 620 598 600 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0040018-b016">16</xref>
###xml 719 721 699 701 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0040018-b027">27</xref>
###xml 890 897 862 869 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 52 57 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 151 156 <span type="species:ncbi:9606">Human</span>
###xml 199 204 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 272 277 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 312 317 <span type="species:ncbi:9606">human</span>
###xml 418 423 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 460 465 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 691 696 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Old World monkey Trim5alpha very efficiently blocks HIV-1 infection at an early step in the viral replication cycle, immediately after cellular entry. Human Trim5alpha is also able to interfere with HIV-1 infection, albeit less efficiently. Although this may suggest that HIV-1 has at least partially adapted to human Trim5alpha, we have recently provided the first evidence that Trim5alpha might still play a role in HIV-1 pathogenesis [27]. We observed that HIV-1 variants containing a H87Q mutation in the cyclophilin A binding region of capsid, which has previously been associated with escape from Trim5alpha [11-16], developed during the late phase of infection in a proportion of the HIV-1 infected individuals [27]. The emergence of these Trim5alpha escape variants was preceded by a prolonged asymptomatic phase implying that Trim5alpha contributed to control of virus replication in vivo and concomitantly selected for Trim5alpha resistant variants.
###end p 41
###begin p 42
###xml 39 44 39 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Trim5</italic>
###xml 229 237 221 229 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 239 241 231 233 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0040018-b028">28</xref>
###xml 242 244 234 236 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0040018-b030">30</xref>
###xml 245 247 237 239 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0040018-b032">32</xref>
###xml 33 38 <span type="species:ncbi:9606">human</span>
###xml 129 134 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 200 205 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 430 435 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Two genetic polymorphisms in the human Trim5 gene have recently been described to affect the antiviral activity of Trim5alpha on HIV-1. The H43Y polymorphism has been associated with an impaired anti-HIV-1 activity of Trim5alpha in vitro [28,30,32]. In agreement, we here observed that a 43YY homozygous genotype was predictive for an accelerated progression to AIDS, independent of CD4 cell counts, viral RNA load in plasma, and HIV-1 coreceptor usage at 18-30 months after seroconversion.
###end p 42
###begin p 43
###xml 83 85 83 85 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0040018-b029">29</xref>
###xml 86 88 86 88 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0040018-b032">32</xref>
###xml 326 328 326 328 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0040018-b029">29</xref>
###xml 647 649 647 649 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0040018-b029">29</xref>
###xml 650 652 650 652 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0040018-b031">31</xref>
###xml 1321 1323 1321 1323 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0040018-b032">32</xref>
###xml 1743 1745 1742 1744 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0040018-b030">30</xref>
###xml 56 61 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1116 1124 <span type="species:ncbi:9606">patients</span>
###xml 1293 1298 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
In previous studies, the H43Y genotype had no effect on HIV-1 disease progression [29-32]. Speelmon et al. observed no significant difference in viral RNA load in the period from 100 days until 2 years post infection between individuals who were homozygous (YY), heterozygous (HY) or wild type (HH) for amino acid residue 43 [29]. In agreement, we also did not observe a difference in viral RNA load at 2 years after seroconversion between the H43Y genotypic groups (data not shown). However, the studies by Speelmon et al. and by Goldschmidt et al. did also not show significant differences in CD4 cell decline between the H43Y genotypic groups [29,31]. Due to the low minor allele frequency for H43Y in the study population by Speelmon et al., which had a size of only 90 individuals, the number of individuals homozygous for the 43Y genotype might have been to low to observe significant difference between the genotypes. The discrepancy between our results and those of Goldschmidt et al. may lie in their relatively short average follow-up time of 3.2 years as compared to the average follow-up of 7.9 years on patients in our study. Nakayama et al. observed similar frequencies of homozygous 43YY and heterozygous 43HY genotypes in progressors and LTNP in a study population of Japanese HIV-1 infected individuals [32]. In our Amsterdam cohort however, none of the individuals homozygous for the 43YY genotype had an asymptomatic follow up of 10 years or more. Javanbakht et al. observed no significant differences in progression to CD4 T cell counts below 200 cells per mul blood, AIDS defining events or AIDS related deaths associated with the different H43Y genotypes in two large cohorts of African Americans and European Americans [30]. In the African American population the frequency of individuals homozygous for the 43YY genotype is however very low which might account for the discrepancy with our data. However, the minor allele frequency for H43Y in the European American cohort is similar to the frequency in the Amsterdam cohort (0.114 and 0.115 respectively). Unfortunately, lack of details on their European American cohort and their analyses make it difficult to bring up potential explanations for the inconsistency in results.
###end p 43
###begin p 44
###xml 107 115 103 111 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 117 119 113 115 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0040018-b030">30</xref>
###xml 156 158 152 154 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0040018-b028">28</xref>
###xml 159 161 155 157 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0040018-b029">29</xref>
###xml 162 164 158 160 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0040018-b031">31</xref>
###xml 202 204 198 200 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0040018-b029">29</xref>
###xml 205 207 201 203 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0040018-b031">31</xref>
###xml 493 496 489 492 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4.5</sup>
###xml 78 83 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
The R136Q polymorphism has been associated with a slight increase of the anti-HIV-1 activity of Trim5alpha in vitro [30], although not confirmed by others [28,29,31]. In agreement with earlier reports [29,31], we did not observe an effect of the R136Q polymorphism on disease progression. A protective effect of the 136Q variant was only evident in the phase of infection when X4-variants were present, where a delayed rise in viral load above the median load during progression to disease (104.5 copies per ml) was observed in individuals who were homozygous (QQ) or heterozygous (RQ) for the 136Q genotype as compared to individuals with the wild type genotype (RR).
###end p 44
###begin p 45
###xml 143 150 135 142 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 362 364 354 356 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0040018-b035">35</xref>
###xml 365 367 357 359 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0040018-b037">37</xref>
###xml 575 577 567 569 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0040018-b035">35</xref>
###xml 578 580 570 572 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0040018-b036">36</xref>
###xml 255 260 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 900 905 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
The protective effect of the 136Q Trim5alpha variant on disease progression only after the emergence of X4-variants, may imply that Trim5alpha in vivo affects replication of X4-variants more efficiently than R5-variants. X4-variants develop in 50% of the HIV-1 infected individuals during the natural course of infection after which R5- and X4-variants coexist [35-37]. While co-existing R5- and X4-variants infect memory CD4 T cells that co-express CCR5 and CXCR4, X4-variants have the unique ability to additionally infect naive CD4 T cells that selectively express CXCR4 [35,36]. Here we observed that naive CD4 T cells expressed higher levels of Trim5alpha as compared to memory CD4 T cells. It is tempting to speculate that high Trim5alpha expression levels in naive T cells in combination with a more potent antiviral activity associated with the 136Q polymorphism provide prolonged control of HIV-1 replication in carriers of X4-variants.
###end p 45
###begin p 46
###xml 66 71 66 71 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Trim5</italic>
###xml 210 212 210 212 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0040018-b029">29</xref>
###xml 314 316 314 316 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0040018-b029">29</xref>
###xml 760 762 760 762 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0040018-b029">29</xref>
###xml 1058 1060 1058 1060 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0040018-b030">30</xref>
###xml 1249 1251 1249 1251 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0040018-b029">29</xref>
###xml 164 169 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 287 292 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 467 472 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 886 891 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1221 1226 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Recently a G to C polymorphism at position -2 in the 5'UTR of the Trim5 gene (-2G/C; rs3824949) in combination with the R136Q polymorphism has been associated with HIV-1 susceptibility and disease progression [29]. Speelmon et al. observed an enrichment of the 136Q/-2G haplotype in the HIV-1 positive population [29], however we were unable to confirm this and observed an equal distribution of the -2G/C polymorphism in combination with the 136Q allele between the HIV-1 positive population and the control group. However, the 136Q allele in combination with the -2GG genotype was associated with accelerated disease progression in our study population. Speelmon et al. observed an association between a faster CD4 T cell decline and the 136R/-2G haplotype [29], but we were unable to confirm this. In our study population we observed a -2C allele frequency of 0.486 and 0.418 in the HIV-1 positive study population and the control group, respectively, which is similar to the frequencies in the European American population reported by Javanbakht et al. [30]. However the frequencies for the -2C allele frequencies in the study populations of Speelmon et al. were much lower (0.38 in exposed seronegatives and 0.31 in HIV-1 infected population) [29]. Therefore, it cannot be excluded that differences in the distribution of the -2G/C polymorphism in different study populations account for the observed discrepancies in results.
###end p 46
###begin p 47
Our data confirm a role of Trim5alpha in the clinical course of infection. In addition, they show that different genetic variants in Trim5alpha are associated with a differential clinical course of infection. Overall, these results may encourage exploiting the possibility of using Trim5alpha or alike derivatives in antiviral strategies.
###end p 47
###begin title 48
Materials and Methods
###end title 48
###begin title 49
###xml 6 18 <span type="species:ncbi:9606">participants</span>
Study participants.
###end title 49
###begin p 50
###xml 204 205 204 205 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0040018-b001">1</xref>
###xml 758 760 758 760 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0040018-b034">34</xref>
###xml 1031 1032 1031 1032 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0040018-b004">4</xref>
###xml 48 51 <span type="species:ncbi:9606">men</span>
###xml 125 130 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 305 316 <span type="species:ncbi:9606">participant</span>
###xml 329 341 <span type="species:ncbi:9606">participants</span>
###xml 397 400 <span type="species:ncbi:9606">men</span>
###xml 419 424 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 619 624 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 654 666 <span type="species:ncbi:9606">participants</span>
###xml 797 809 <span type="species:ncbi:9606">participants</span>
###xml 863 875 <span type="species:ncbi:9606">participants</span>
The study population, 364 Caucasian, homosexual men enrolled in the Amsterdam Cohort studies (ACS) on the natural history of HIV-1 infection between October 1984 and March 1986, was previously described [1]. The censor date of our study was set at the first day of effective antiretroviral therapy of the participant. Of the 364 participants, 131 seroconverted during the study. The remaining 233 men were positive for HIV-1 antibodies at entry between October 1984 and April 1985. In previous epidemiological studies, the time since seroconversion of these prevalent cases has been estimated based on the incidence of HIV-1 infection amongst homosexual participants of the Amsterdam Cohort and was on average 1.5 years before entry into the cohort studies [34]. For analysis, we combined the 131 participants with documented seroconversion and 233 seroprevalent participants with an imputed seroconversion date as one study group, since previous studies have not revealed differences in AIDS-free survival between the two groups [4].
###end p 50
###begin p 51
The ACS has been conducted in accordance with the ethical principles set out in the declaration of Helsinki and written informed consent is obtained prior to data collection. The study was approved by the Amsterdam Medical Center institutional medical ethics committee.
###end p 51
###begin title 52
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Trim5</italic>
Trim5 genotyping.
###end title 52
###begin p 53
###xml 94 99 94 99 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Trim5</italic>
###xml 132 137 132 137 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Trim5</italic>
###xml 30 42 <span type="species:ncbi:9606">participants</span>
DNA samples of 327 out of 364 participants of the Amsterdam Cohort studies were available for Trim5 genotyping. For analysis of the Trim5 R136Q polymorphism (rs10838525), DNA samples were amplified by PCR using Taq DNA polymerase (Invitrogen) and primer pair Trim5-F (5'-ATGGCTTCTGGAATCCTGGTTAATG-3') and Trim5-R136Q-R (5'-CCCGGGTCTCAGGTCTATCATG-3'). The following amplification cycles were used: 5min 95degreesC; 35 cycles of 30s 95degreesC, 30s 50degreesC, 90s 72degreesC; 5min 72degreesC. Subsequently PCR products were purified and subjected to a restriction digest with 1U Ava1 (1.5 hour 37degreesC; NEB) and analyzed on a 1% agarose gel. A PCR product containing an R at position 136 will result in digestion of the PCR product into a 405bp and 121bp product. A PCR product containing a Q at position 136 will result in a 526bp (undigested) product. For conformation, 15 samples (5 homozygous 136R, 5 homozygous 136Q and 5 heterozygous 136QR) have been sequenced with the ABI prism BigDue Terminator kit V1.1 (Applied Biosystems) using primers Trim5-F and Trim5-R136Q-R). Sequences were analyzed on an ABI 3130XL Genetic Analyzer.
###end p 53
###begin p 54
###xml 20 25 20 25 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Trim5</italic>
For analysis of the Trim5 H43Y polymorphism (rs3740996), DNA samples were amplified by PCR using Taq DNA polymerase (Invitrogen) and primer pair Trim5-F and Trim5-H43Y-R (5'-GGCTGGTAACTGATCCGGCAC-3'). For analysis of the -2GC polymorphism (rs3824949), DNA samples were amplified by PCR using Taq DNA polymerase (Invitrogen) and primer pair Tr5-2GC (5'-GCAGGGATCTGTGAACAAGAGG-3') and Trim5-H43Y-R. The following amplification cycles were used: 5min 95degreesC; 35 cycles of 30s 95degreesC, 30s 55degreesC, 90s 72degreesC; 5min 72degreesC. Subsequently PCR products were purified and sequenced with the ABI prism BigDue Terminator kit V1.1 (Applied Biosystems) using primers Trim5-F and Trim5-H43Y-R for H43Y and Tr5-2GC and Trim5-H43Y-R for -2GC. Sequences were analyzed on an ABI 3130XL Genetic Analyzer.
###end p 54
###begin title 55
FACS sorting naive and memory CD4 T cells.
###end title 55
###begin p 56
Cryopreserved PBMC were stained with antibodies against CD4 (tricolor conjugated; Caltag Laboratories), CD45RO (FITC conjugated; BD Biosciences) and CD27 (phycoerythrin conjugated; Caltag Laboratories), and sorted using a MoFlo cell sorter (Cytomation Inc.). Cells were sorted in two different cell populations: naive (CD45RO-CD27+) CD4 T cells and memory (CD45RO+) CD4 T cells.
###end p 56
###begin title 57
RNA isolation and quantitative PCR.
###end title 57
###begin p 58
###xml 438 439 425 426 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 60 65 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Total RNA was isolated from naive and memory CD4 cells from HIV-1 infected individuals or healthy donors, using the RNeasy mini kit (Qiagen, Hilden, Germany). Subsequently, cDNA was prepared using the SuperScripttrade mark First-Strand Synthesis System for RT-PCR (In Vitrogen). Trim5alpha mRNA levels were analyzed by SYBR green qPCR using the LightCycler (Roche). The reaction mix contained 20 mM Tris-HCl (pH 8.4), 50 mM KCl, 3 mM MgCl2, 200 muM dNTP, 250 mug/ml BSA, 500 nM primers, SYBR green I nucleic acid gel stain 40,000x diluted in water, and 0.6 U platinum Taq DNA polymerase (In Vitrogen). The following primer sets were used for detection of Trim5alpha cDNA: Trim5alpha -RNA-F 5'-ccaggatagttccttccatac-3' and Trim5alpha-R 5'-agagcttggtgagcacagagtc-3'. Serial dilution of plasmid DNA containing cDNA of Trim5alpha were used as a standard curve. To correct for differences in the cDNA input, levels of beta-actin cDNA were analyzed by a SYBR green qPCR using the following primer set: BA-RNA-F 5'-ggcccagtcctctcccaagtccac-3' and BA-RNA-R 5'-ggtaagccctggctgcctccacc-3'. A serial dilution of 8E5 cells was used as a standard curve for beta-actin. SYBR green qPCR was performed using the following program on the LightCycler: (1) preincubation and denaturation: 50degreesC for 2 min, 95degreesC for 2 min; (2) amplification and quantification: 45 cycles of 95degreesC for 5 sec, 55degreesC for 15 sec, 72degreesC for 15 sec; (3) melting curve: 95degreesC for 0 sec, 65degreesC for 15 min, 95degreesC for 0 sec with a temperature transition rate of 0.1degreesC/sec. Specificity of the PCR products measured using the SYBR green method was confirmed by a melting curve.
###end p 58
###begin title 59
Statistical analysis.
###end title 59
###begin p 60
###xml 135 140 135 140 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Trim5</italic>
###xml 317 319 317 319 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0040018-b038">38</xref>
###xml 369 371 369 371 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0040018-b039">39</xref>
###xml 450 453 449 452 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4.5</sup>
###xml 555 557 554 556 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0040018-b037">37</xref>
###xml 787 789 786 788 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0040018-b040">40</xref>
###xml 790 792 789 791 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat-0040018-b041">41</xref>
###xml 527 534 <span type="species:ncbi:9606">patient</span>
Kaplan Meier and Cox proportional hazard analysis were performed to study the relation between the R136Q and H43Y polymorphisms in the Trim5 gene and disease progression. The following endpoints were considered for analysis: (1) AIDS according to the 1987 Centers for Disease Control and Prevention (CDC) definition [38]; (2) AIDS according to the 1993 CDC definition [39]; (3) CD4 T cell counts below 200 cells/mul blood; (4) viral RNA load above 104.5 copies per ml blood plasma; (5) detection of X4-variants by coculture of patient PBMC and MT2 cells [37]. Fisher's exact test was used to analyze an association between the R136Q, H43Y polymorphisms and prevalence of X4-variants. Sequential Bonferroni correction (Simes-Hochberg method) was used to correct for multiple comparisons [40,41].
###end p 60
###begin p 61
###xml 116 120 116 120 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCR5</italic>
Univariate and multivariate relative hazards were calculated at 2 years after seroconversion for the H43Y genotype, CCR5 genotype, presence of X4-variants at 18-30 months after seroconversion, CD4 T cells at 18-30 months after seroconversion and viral RNA load at 18-30 months after seroconversion.
###end p 61
###begin p 62
###xml 88 89 84 85 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">T</italic>
Trim5alpha mRNA levels in naive and memory CD4 T cells were compared using the Students T test.
###end p 62
###begin p 63
###xml 74 77 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 327 330 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 494 506 <span type="species:ncbi:9606">participants</span>
This study was performed as part of the Amsterdam Cohort Studies (ACS) on HIV infection and AIDS, a collaboration between the Amsterdam Health Service, the Academic Medical Centre of the University of Amsterdam, Sanquin Blood Supply Foundation, and the University Medical Centre Utrecht (). The ACS are part of the Netherlands HIV Monitoring Foundation and financially supported by the Netherlands National Institute for Public Health and the Environment. We are greatly indebted to all cohort participants for their continuous participation. The authors thank Judith Burger and Brigitte Boeser-Nunnink for excellent technical assistance. The authors thank Ronald Geskus for helpful discussions.
###end p 63
###begin title 64
Abbreviations
###end title 64
###begin p 65
Amsterdam Cohort Studies
###end p 65
###begin p 66
Centers for Disease Control and Prevention
###end p 66
###begin p 67
###xml 11 16 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
CCR5 using HIV-1 variants
###end p 67
###begin p 68
relative hazard
###end p 68
###begin p 69
tripartite interaction motif
###end p 69
###begin p 70
###xml 12 17 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
CXCR4 using HIV-1 variants
###end p 70
###begin title 71
References
###end title 71
###begin article-title 72
###xml 61 66 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Association between CCR5 genotype and the clinical course of HIV-1 infection
###end article-title 72
###begin article-title 73
###xml 59 64 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Contrasting genetic influence of CCR2 and CCR5 variants on HIV-1 infection and disease progression. Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort (SFCC), ALIVE Study
###end article-title 73
###begin article-title 74
Genetic restriction of AIDS pathogenesis by an SDF-1 chemokine gene variant. ALIVE Study, Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort (SFCC)
###end article-title 74
###begin article-title 75
###xml 82 117 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Role of CCR2 genotype in the clinical course of syncytium-inducing (SI) or non-SI human immunodeficiency virus type 1 infection and in the time to conversion to SI virus variants
###end article-title 75
###begin article-title 76
###xml 29 34 <span type="species:ncbi:9606">human</span>
###xml 91 96 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Influence of combinations of human major histocompatibility complex genes on the course of HIV-1 infection
###end article-title 76
###begin article-title 77
###xml 39 74 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Characterization of HLA-B57-restricted human immunodeficiency virus type 1 Gag- and RT-specific cytotoxic T lymphocyte responses
###end article-title 77
###begin article-title 78
###xml 11 16 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Control of HIV-1 viremia and protection from AIDS are associated with HLA-Bw4 homozygosity
###end article-title 78
###begin article-title 79
###xml 118 153 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Major histocompatibility complex genotype is associated with disease progression and virus load levels in a cohort of human immunodeficiency virus type 1-infected Caucasians and African Americans
###end article-title 79
###begin article-title 80
###xml 52 57 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys
###end article-title 80
###begin article-title 81
###xml 53 63 <span type="species:ncbi:9505">owl monkey</span>
###xml 78 83 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Cyclophilin A retrotransposition into TRIM5 explains owl monkey resistance to HIV-1
###end article-title 81
###begin article-title 82
###xml 39 44 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Abrogation of postentry restriction of HIV-1-based lentiviral vector transduction in simian cells
###end article-title 82
###begin article-title 83
###xml 20 55 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Influence of gag on human immunodeficiency virus type 1 species-specific tropism
###end article-title 83
###begin article-title 84
###xml 45 80 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Species-specific tropism determinants in the human immunodeficiency virus type 1 capsid
###end article-title 84
###begin article-title 85
###xml 117 152 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Binding and susceptibility to postentry restriction factors in monkey cells are specified by distinct regions of the human immunodeficiency virus type 1 capsid
###end article-title 85
###begin article-title 86
Specific recognition and accelerated uncoating of retroviral capsids by the TRIM5alpha restriction factor
###end article-title 86
###begin article-title 87
###xml 42 47 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Efficient transduction of simian cells by HIV-1 based lentiviral vectors that contain mutations in the capsid protein
###end article-title 87
###begin article-title 88
###xml 15 50 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Restriction of human immunodeficiency virus type 1 by TRIM-CypA occurs with rapid kinetics and independently of cytoplasmic bodies, ubiquitin, and proteasome activity
###end article-title 88
###begin article-title 89
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human tripartite motif 5alpha domains responsible for retrovirus restriction activity and specificity
###end article-title 89
###begin article-title 90
The contribution of RING and B-box 2 domains to retroviral restriction mediated by monkey TRIM5alpha
###end article-title 90
###begin article-title 91
###xml 4 9 <span type="species:ncbi:9606">human</span>
###xml 14 34 <span type="species:ncbi:9534">African green monkey</span>
The human and African green monkey TRIM5alpha genes encode Ref1 and Lv1 retroviral restriction factor activities
###end article-title 91
###begin article-title 92
Retrovirus resistance factors Ref1 and Lv1 are species-specific variants of TRIM5alpha
###end article-title 92
###begin article-title 93
###xml 52 75 <span type="species:ncbi:11786">murine leukemia viruses</span>
###xml 79 84 <span type="species:ncbi:9606">human</span>
TRIM5alpha mediates the postentry block to N-tropic murine leukemia viruses in human cells
###end article-title 93
###begin article-title 94
###xml 62 66 <span type="species:ncbi:9913">cows</span>
Evolution of a cytoplasmic tripartite motif (TRIM) protein in cows that restricts retroviral infection
###end article-title 94
###begin article-title 95
Retrovirus restriction by TRIM5alpha variants from Old World and New World primates
###end article-title 95
###begin article-title 96
###xml 34 39 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 44 65 <span type="species:ncbi:11786">murine leukemia virus</span>
Trim5alpha protein restricts both HIV-1 and murine leukemia virus
###end article-title 96
###begin article-title 97
###xml 28 63 <span type="species:ncbi:11709">human immunodeficiency virus type 2</span>
###xml 68 104 <span type="species:ncbi:11711">simian immunodeficiency virus SIVmac</span>
Differential restriction of human immunodeficiency virus type 2 and simian immunodeficiency virus SIVmac by TRIM5alpha alleles
###end article-title 97
###begin article-title 98
###xml 80 85 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
The presence of the Trim5alpha escape mutation H87Q in the capsid of late stage HIV-1 variants is preceded by a prolonged asymptomatic infection phase
###end article-title 98
###begin article-title 99
###xml 94 100 <span type="species:ncbi:9606">humans</span>
High-frequency persistence of an impaired allele of the retroviral defense gene TRIM5alpha in humans
###end article-title 99
###begin article-title 100
###xml 72 107 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Genetic association of the antiviral restriction factor TRIM5alpha with human immunodeficiency virus type 1 infection
###end article-title 100
###begin article-title 101
###xml 11 16 <span type="species:ncbi:9606">human</span>
###xml 91 119 <span type="species:ncbi:12721">human immunodeficiency virus</span>
Effects of human TRIM5alpha polymorphisms on antiretroviral function and susceptibility to human immunodeficiency virus infection
###end article-title 101
###begin article-title 102
###xml 15 20 <span type="species:ncbi:9606">human</span>
###xml 44 49 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Role of common human TRIM5alpha variants in HIV-1 disease progression
###end article-title 102
###begin article-title 103
###xml 30 35 <span type="species:ncbi:9606">human</span>
###xml 65 100 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Wild type and H43Y variant of human TRIM5alpha show similar anti-human immunodeficiency virus type 1 activity both in vivo and in vitro
###end article-title 103
###begin article-title 104
###xml 20 25 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Prognostic value of HIV-1 syncytium-inducing phenotype for rate of CD4+ cell depletion and progression to AIDS
###end article-title 104
###begin article-title 105
###xml 39 42 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
On the inclusion of prevalent cases in HIV/AIDS natural history studies through a marker-based estimate of time since seroconversion
###end article-title 105
###begin article-title 106
###xml 8 13 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
In vivo HIV-1 infection of CD45RA(+)CD4(+) T cells is established primarily by syncytium-inducing variants and correlates with the rate of CD4(+) T cell decline
###end article-title 106
###begin article-title 107
###xml 117 122 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Differential coreceptor expression allows for independent evolution of non-syncytium-inducing and syncytium-inducing HIV-1
###end article-title 107
###begin article-title 108
###xml 0 5 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
HIV-1 biological phenotype in long-term infected individuals evaluated with an MT-2 cocultivation assay
###end article-title 108
###begin article-title 109
Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome
###end article-title 109
###begin article-title 110
###xml 39 42 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescentes and adults
###end article-title 110
###begin article-title 111
An improved Bonferroni procedure for multiple tests of significance
###end article-title 111
###begin article-title 112
A sharper Bonferroni procedure for multiple tests of significance
###end article-title 112
###begin p 113
currency Current address: Department of Experimental Immunology, Amsterdam Medical Center, Amsterdam, The Netherlands
###end p 113
###begin p 114
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Author contributions.</bold>
Author contributions. HS and NAK conceived and designed the experiments and wrote the paper. DvM, MANR, CB, and KvD performed the experiments. DvM and NAK analyzed the data.
###end p 114
###begin p 115
###xml 0 8 0 8 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding.</bold>
Funding. This work has been supported by the Netherlands Organization for Scientific Research (NWO grant number 916.36.024 and 9120.6046), the Dutch AIDS fund (grant 2004062), and the Landsteiner Foundation for Blood Transfusion Research (grant 0435).
###end p 115
###begin p 116
###xml 0 20 0 20 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing interests.</bold>
Competing interests. The authors have declared that no competing interests exist.
###end p 116

